Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds

Jul 15, 2024 | Press Releases

CINCINNATI, July 15, 2024 — Onconetix, Inc. (“Onconetix” or the “Company”) (Nasdaq: ONCO), today announced the closing of the previously announced exercise of certain existing warrants to purchase 7,458,642 shares of its common stock...

Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds

Jul 11, 2024 | Press Releases

CINCINNATI, Ohio, July 11, 2024 — Onconetix, Inc. (“Onconetix” or the “Company”) (Nasdaq: ONCO), today announced it has entered into definitive agreements for the immediate exercise of certain existing warrants to purchase 7,458,642...

Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds

Jul 11, 2024 | Press Releases

CINCINNATI, Ohio, July 11, 2024 — Onconetix, Inc. (“Onconetix” or the “Company”) (Nasdaq: ONCO), today announced it has entered into definitive agreements for the immediate exercise of certain existing warrants to purchase 7,458,642...

Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors

Feb 13, 2024 | Press Releases

CINCINNATI, Feb. 13, 2024 — Onconetix, Inc., (Nasdaq: ONCO) (“Onconetix” or the “Company”), a commercial stage biotechnology company focused on developing and commercializing therapeutics, diagnostics, and services for clinicians and...

Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors

Feb 13, 2024 | Press Releases

CINCINNATI, Feb. 13, 2024 — Onconetix, Inc., (Nasdaq: ONCO) (“Onconetix” or the “Company”), a commercial stage biotechnology company focused on developing and commercializing therapeutics, diagnostics, and services for clinicians and...

Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders

Dec 19, 2023 | Press Releases

CINCINNATI, Dec. 19, 2023 — Onconetix, Inc., (Nasdaq: BWV) (“Onconetix” or the “Company”) today issued the following shareholder letter from the Company’s Chief Executive Officer, Dr. Neil Campbell. To Our Valued Shareholders, As...